Cargando…
A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel
AIMS AND METHODS: This was a 6-month, open label, multinational, observational study in hypogonadal men treated with daily titrated dose of 50, 75, or 100 mg 1% testosterone gel (AndroGel®) in community practice. Primary outcome was effect of treatment on hypogonadal symptoms and quality of life as...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Informa UK Ltd.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956632/ https://www.ncbi.nlm.nih.gov/pubmed/24274081 http://dx.doi.org/10.3109/13685538.2013.858113 |
_version_ | 1782307689378873344 |
---|---|
author | Pexman-Fieth, Claire Behre, Hermann M. Morales, Alvaro Kan-Dobrosky, Natalia Miller, Michael G. |
author_facet | Pexman-Fieth, Claire Behre, Hermann M. Morales, Alvaro Kan-Dobrosky, Natalia Miller, Michael G. |
author_sort | Pexman-Fieth, Claire |
collection | PubMed |
description | AIMS AND METHODS: This was a 6-month, open label, multinational, observational study in hypogonadal men treated with daily titrated dose of 50, 75, or 100 mg 1% testosterone gel (AndroGel®) in community practice. Primary outcome was effect of treatment on hypogonadal symptoms and quality of life as assessed by Aging Males’ Symptoms (AMS) scale. Secondary objectives included erectile dysfunction (International Index of Erectile Function [IIEF]), fatigue (Multidimensional Fatigue Inventory [MFI]), and surrogates for body composition (waist circumference, body mass index [BMI]). RESULTS: Seven hundred and ninety-nine of the 1053 men enrolled had follow-up data at 6 months, 81.2% had ≥1 testosterone value in the normal range during the study. Substantial and significant improvements were observed in mean AMS score (−29%), IIEF score (+115.7%), and MFI scores (−21.5%). Further beneficial effects were significant decreases in mean BMI (−0.8 kg/m(2)) and waist circumference (−3.3 cm). Younger age quartiles showed greater improvements in AMS, MFI, BMI, and waist circumference than older quartiles. IIEF scores, however, did not differ significantly by age category. CONCLUSIONS: Substantial improvements in hypogonadal symptoms, quality of life, fatigue, erectile dysfunction, and libido/sexual desire were observed. Adverse drug reactions were experienced by 7.5% of the safety population over the 6-month study period. |
format | Online Article Text |
id | pubmed-3956632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Informa UK Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-39566322014-03-18 A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel Pexman-Fieth, Claire Behre, Hermann M. Morales, Alvaro Kan-Dobrosky, Natalia Miller, Michael G. Aging Male Original Article AIMS AND METHODS: This was a 6-month, open label, multinational, observational study in hypogonadal men treated with daily titrated dose of 50, 75, or 100 mg 1% testosterone gel (AndroGel®) in community practice. Primary outcome was effect of treatment on hypogonadal symptoms and quality of life as assessed by Aging Males’ Symptoms (AMS) scale. Secondary objectives included erectile dysfunction (International Index of Erectile Function [IIEF]), fatigue (Multidimensional Fatigue Inventory [MFI]), and surrogates for body composition (waist circumference, body mass index [BMI]). RESULTS: Seven hundred and ninety-nine of the 1053 men enrolled had follow-up data at 6 months, 81.2% had ≥1 testosterone value in the normal range during the study. Substantial and significant improvements were observed in mean AMS score (−29%), IIEF score (+115.7%), and MFI scores (−21.5%). Further beneficial effects were significant decreases in mean BMI (−0.8 kg/m(2)) and waist circumference (−3.3 cm). Younger age quartiles showed greater improvements in AMS, MFI, BMI, and waist circumference than older quartiles. IIEF scores, however, did not differ significantly by age category. CONCLUSIONS: Substantial improvements in hypogonadal symptoms, quality of life, fatigue, erectile dysfunction, and libido/sexual desire were observed. Adverse drug reactions were experienced by 7.5% of the safety population over the 6-month study period. Informa UK Ltd. 2014-03 2013-11-25 /pmc/articles/PMC3956632/ /pubmed/24274081 http://dx.doi.org/10.3109/13685538.2013.858113 Text en © 2014 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the source is credited. |
spellingShingle | Original Article Pexman-Fieth, Claire Behre, Hermann M. Morales, Alvaro Kan-Dobrosky, Natalia Miller, Michael G. A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel |
title | A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel |
title_full | A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel |
title_fullStr | A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel |
title_full_unstemmed | A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel |
title_short | A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel |
title_sort | 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956632/ https://www.ncbi.nlm.nih.gov/pubmed/24274081 http://dx.doi.org/10.3109/13685538.2013.858113 |
work_keys_str_mv | AT pexmanfiethclaire a6monthobservationalstudyofenergysexualdesireandbodyproportionsinhypogonadalmentreatedwithatestosterone1gel AT behrehermannm a6monthobservationalstudyofenergysexualdesireandbodyproportionsinhypogonadalmentreatedwithatestosterone1gel AT moralesalvaro a6monthobservationalstudyofenergysexualdesireandbodyproportionsinhypogonadalmentreatedwithatestosterone1gel AT kandobroskynatalia a6monthobservationalstudyofenergysexualdesireandbodyproportionsinhypogonadalmentreatedwithatestosterone1gel AT millermichaelg a6monthobservationalstudyofenergysexualdesireandbodyproportionsinhypogonadalmentreatedwithatestosterone1gel AT pexmanfiethclaire 6monthobservationalstudyofenergysexualdesireandbodyproportionsinhypogonadalmentreatedwithatestosterone1gel AT behrehermannm 6monthobservationalstudyofenergysexualdesireandbodyproportionsinhypogonadalmentreatedwithatestosterone1gel AT moralesalvaro 6monthobservationalstudyofenergysexualdesireandbodyproportionsinhypogonadalmentreatedwithatestosterone1gel AT kandobroskynatalia 6monthobservationalstudyofenergysexualdesireandbodyproportionsinhypogonadalmentreatedwithatestosterone1gel AT millermichaelg 6monthobservationalstudyofenergysexualdesireandbodyproportionsinhypogonadalmentreatedwithatestosterone1gel |